Ginkgo

Concentric by Ginkgo Partners with Penn State University on Zoonotic Disease Biosurveillance Research Supported by USDA Grant

Retrieved on: 
Tuesday, October 24, 2023
Pennsylvania State University, Concentric objects, Ginkgo Bioworks, NYSE, Health, Therapy, Vaccine, Government, SARS-CoV-2, Human, Biosecurity, Ministry of Agriculture, Animal Industry and Fisheries (Uganda), Ginkgo, USDA, Infection, Research, Coyote, Deer, Raccoon, Biology, Risk, Animal, Animal and Plant Health Inspection Service, U.S. Department of Defense Strategy for Operating in Cyberspace, DNA, Hunting

 BOSTON and UNIVERSITY PARK, Pa., Oct. 24, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced it is joining efforts with Penn State University to integrate its biosurveillance capabilities into the university's research of 58 wildlife species for SARS-CoV-2 to monitor potential spillover to humans. The initiative is supported by a cooperative agreement awarded to Penn State from the U.S. Department of Agriculture Animal and Plant Health Inspection Service.

Key Points: 
  • The initiative is supported by a cooperative agreement awarded to Penn State from the U.S. Department of Agriculture Animal and Plant Health Inspection Service.
  • In partnering with Concentric by Ginkgo, the university will gain access to the biosurveillance research and analytics capabilities used by government institutions to help build more stable and robust biosecurity infrastructure.
  • "We are thrilled to collaborate with Penn State, a land-grant institution at the forefront of zoonotic SARS-CoV-2 biosurveillance, and we are proud to participate in the work USDA is doing to lead on biosecurity," said Matt McKnight, General Manager for Biosecurity at Ginkgo Bioworks.
  • The partners believe the research will provide data that can help support informed decision-making by public health officials.

Government of Serbia and Ginkgo Bioworks Announce Bioeconomy Collaboration in BIO4 Campus

Retrieved on: 
Thursday, October 19, 2023
MSD, Government of Serbia, Government, BGI, AstraZeneca, Biodiversity, Ginkgo Bioworks, NYSE, Innovation, Health, Food, Biotechnology, Motivation, Ministry of Science, Technological Development and Innovation (Serbia), Doctor of Philosophy, Ginkgo, Entrepreneurship, Memorandum of understanding, Research, Fourth Industrial Revolution, Swarrnim Startup & Innovation University, Biology, Ecosystem, Partnership, Roche, Synthetic biology, Agriculture, Map, Startup accelerator, DNA, Forestry, Pharmaceutical industry, Science, Takeda, Merck, Pfizer

The BIO4 campus initiative already gathers more than 1,000 PhD scientists from 17 scientific institutions, and the campus itself will open in 2026.

Key Points: 
  • The BIO4 campus initiative already gathers more than 1,000 PhD scientists from 17 scientific institutions, and the campus itself will open in 2026.
  • Within the envisioned collaboration, companies on the BIO4 campus will have the opportunity to take advantage of incentives to access Ginkgo's platform.
  • Further, under the MoU, Ginkgo and the Government of Serbia will also explore partnerships to develop and implement new biomonitoring capabilities in Serbia.
  • The Centre is part of the C4IR network, and co-founded by the World Economic Forum and the Government of Serbia.

Persephone Biosciences and Ginkgo Bioworks Complete Reusable Bacteroides Anaerobic Engineering Toolkit

Retrieved on: 
Tuesday, October 17, 2023
Health, NYSE, Biology, Cell engineering, DNA, Therapy, Persephone, Environment, Bacteroides, SAN, Software, Commercial, Medical imaging, Antibiotics, Ginkgo

SAN DIEGO and BOSTON, Oct. 17, 2023 /PRNewswire/ -- Persephone Biosciences Inc., a synthetic biology company reimagining patient health through the microbiome, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of their first collaboration together, a Bacteroides engineering toolkit. Under the collaboration, both Persephone and Ginkgo have access to this reusable toolkit. Persephone will utilize the technology to develop a pipeline of microbiome therapeutics, and Ginkgo can use the technology as part of its broader platform offering for future customers.

Key Points: 
  • Under the collaboration, both Persephone and Ginkgo have access to this reusable toolkit.
  • Persephone will utilize the technology to develop a pipeline of microbiome therapeutics, and Ginkgo can use the technology as part of its broader platform offering for future customers.
  • The technology comprises a set of generalizable genetic tools which can facilitate rapid Bacteroides engineering, including in the high-throughput anaerobic engineering context.
  • Over the course of this collaboration, Ginkgo incorporated its flagship hardware and software workflows under an anaerobic blanket, meaningfully extending its cell engineering platform capabilities to perform productively in an anaerobic environment.

Zenfold Leverages Ginkgo Enzyme Services to Enable Veterinary Active Ingredient Development with Sustainable Biology

Retrieved on: 
Monday, October 16, 2023
Partnership, DNA, A-DNA, Cell engineering, NYSE, Veterinary medicine, Environment, SVP, Biotechnology, Commercial, Fine chemical, Ginkgo

This partnership aims to replace traditional chemical processes in veterinary active ingredient production with a sustainable biological method.

Key Points: 
  • This partnership aims to replace traditional chemical processes in veterinary active ingredient production with a sustainable biological method.
  • "This collaboration marks a significant step forward in Zenfold's mission to bring sustainable manufacturing technology to the veterinary medicine industry," said Dr. BSV Prasad, CEO and Managing Director of Zenfold Sustainable Technologies.
  • "We are excited to partner with Zenfold, which brings a powerful vision of sustainable biotechnology to veterinary active ingredient development.
  • To learn more about the end-to-end services included in Ginkgo Enzyme Services, visit our webpage or email us at [email protected] .

QL AG Announces Partnership with Ginkgo Bioworks to Develop Dairy Proteins

Retrieved on: 
Thursday, October 12, 2023
QL, Climate change, NYSE, Business, Economics, DNA, Protein engineering, Taste, Ginkgo, Ginkgo Bioworks, Fermentation, Business development, Water, Dietary supplement, Dairy

ZURICH, Switzerland and BOSTON, Oct. 12, 2023 /PRNewswire/ -- QL AG, an innovative food technology solutions company, today announced a new collaboration to develop dairy proteins with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity.

Key Points: 
  • ZURICH, Switzerland and BOSTON, Oct. 12, 2023 /PRNewswire/ -- QL AG, an innovative food technology solutions company, today announced a new collaboration to develop dairy proteins with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity.
  • QL AG will tap into Ginkgo's extensive capabilities in strain engineering across multiple chassis organisms to support its goal of providing the market with high-quality nutritionally equivalent dairy proteins.
  • The dairy industry faces significant pressures as climate change continues to lead to a reduction in arable land and water.
  • "By accessing Ginkgo's platform, QL AG can help reduce the cost of producing dairy proteins with fermentation.

Concentric by Ginkgo to Support CDC-Funded Consortium to Develop New AI-Based Technologies for Epidemic Forecasting

Retrieved on: 
Thursday, October 5, 2023
College of Science (Northeastern University), Hospital, Los Alamos National Laboratory, NYSE, Forecasting, Intelligence, Centers for Disease Control and Prevention, Boston University, Government, DNA, Concentric objects, Organization, CDC, Infection, Preventive healthcare, Fred Hutchinson Cancer Research Center, University, Epidemic, Indiana University, Ginkgo, San Diego, Vaccine, Northeastern University, Points of the compass

BOSTON, Oct. 5, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that its biosecurity and public health unit, Concentric by Ginkgo, will partner with Northeastern University, which has received a grant from the Centers of Disease Control and Prevention over the next five years to head an innovation center led by a consortium of organizations designed to help the United States to detect and prepare for the next outbreak of infectious disease.

Key Points: 
  • With the CDC's support, Northeastern will lead a nationwide consortium to develop systems to prepare local communities and hospitals across various geographic regions—including rural areas—for outbreaks, according to the university's announcement .
  • Concentric will contribute its unique blend of computational epidemiology, risk modeling, and social science expertise, supported by an extensive laboratory network.
  • Concentric will also support development of new AI-based early warning systems capable of synthesizing multiple indicators to anticipate sharp changes of disease activity.
  • "We are thrilled to partner with CDC, Northeastern University, and the EPISTORM consortium to develop new technologies for early warning and epidemic forecasting," said Nita Madhav, Head of Epidemiology and Global Risk Analytics at Concentric by Ginkgo.

Nosh.bio Leverages Ginkgo Strain Optimization Services to Enhance Meaty Taste of Mycoprotein

Retrieved on: 
Monday, October 2, 2023
Taste, DNA, Business development, Partnership, Red meat, Business, Fungus, Protein, Ginkgo Bioworks, Ginkgo, EnCap Investments, Mutagenesis, Entrepreneurship, Meat, Biomass, NYSE, Dietary supplement, Food preservation

Nosh.bio will leverage Ginkgo Strain Optimization Services to screen for protein-producing fungi strains with superior sensorial profiles.

Key Points: 
  • Nosh.bio will leverage Ginkgo Strain Optimization Services to screen for protein-producing fungi strains with superior sensorial profiles.
  • By leveraging Ginkgo's ultra high throughput encapsulated screening capabilities, the program aims to produce a mycoprotein that delivers a rich, savory, and natural meaty taste when used in food products.
  • Using such an improved strain can help Nosh.bio develop a mycoprotein that is superior in taste, color, performance, and nutrition.
  • To learn more about Ginkgo Strain Optimization Services, please visit https://www.ginkgobioworks.com/offerings/strain-optimization-services/ .

Concentric By Ginkgo and Texas A&M University Awarded USDA NIFA AFRI Grant to Conduct Genomic Animal Research to Prevent Zoonotic Disease Spillover

Retrieved on: 
Friday, September 29, 2023
Zoonosis, DNA, Human, APHIS, College, Biosecurity, Office of Inspector General, U.S. Department of Health and Human Services, Texas A&M University School of Veterinary Medicine & Biomedical Sciences, Deer, SARS-CoV-2, Texas A&M University, Concentric objects, Livestock, Research, Biomedical sciences, Science, Natural Resources, Animal, Ginkgo Bioworks, Ginkgo, USDA, Risk, Animal and Plant Health Inspection Service, School, College of Agriculture and Life Sciences, Veterinary medicine, Epidemiology, NYSE, Disease, Animal husbandry, Agriculture

BOSTON and COLLEGE STATION, Texas, Sept. 29, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and Texas A&M University today announced they have been jointly awarded a research grant from the U.S. Department of Agriculture's Animal and Plant Health Inspection Service (USDA APHIS) via the National Institute of Food and Agriculture, Agriculture and Food Research Initiative (NIFA AFRI) to study SARS-CoV-2 in white-tailed deer populations in Texas.   

Key Points: 
  • This research is one of the first at-scale studies that will conduct widespread DNA sequencing of white-tailed deer in Texas.
  • White-tailed deer are a farmed animal species that have historically had high positivity rates of SARS-CoV-2 in wild populations throughout the United States.
  • Texas A&M will screen both historic and newly collected samples for the presence of the virus, which will then be sequenced and analyzed by Concentric.
  • "This data and research will provide governments, industry leaders, and academics the information they need to optimize behaviors and provide early warnings to help prevent disease spillover."

Ensovi Leverages Ginkgo Enzyme Services to Optimize Cell-Free Carbon Fixation Process for Biomanufacturing

Retrieved on: 
Thursday, September 28, 2023
DNA, Partnership, Commercialization, Senior, Carbon dioxide, Enzyme, Recycling, Synthetic biology, NYSE, Chemical industry, Ginkgo Bioworks, Ginkgo, Engineering, Acetyl-CoA, Organic, CO2, Fine chemical

Under the terms of the agreement, Ginkgo will support the discovery and development of enzymes needed to bring Ensovi's cell-free biomanufacturing platform to market.

Key Points: 
  • Under the terms of the agreement, Ginkgo will support the discovery and development of enzymes needed to bring Ensovi's cell-free biomanufacturing platform to market.
  • Ginkgo Enzyme Services offers partners end-to-end support for the discovery, engineering, optimization, and scale-up of enzymes for diverse applications.
  • Through the partnership, Ginkgo will leverage its suite of services, including metagenomic enzyme discovery, as well as enzyme optimization for function and stability to support Ensovi's applications.
  • To learn more about Ginkgo Enzyme Services, please visit ginkgobioworks.com/enzyme-services/ .

Ginkgo Bioworks and the Government of the Republic of Madagascar Announce Plans to Develop New Biosecurity Capabilities

Retrieved on: 
Monday, September 25, 2023
DNA, Ivato International Airport, Travel, Biosecurity, Public, COVID-19, Concentric objects, Transport, Meteorology, Government, Republic, Democratic republic, Ginkgo Bioworks, Ginkgo, NYSE, Mobile phone, Vaccine

ANTANANARIVO, Madagascar and BOSTON, Sept. 25, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and the Government of the Republic of Madagascar today announced that they have entered into a Memorandum of Understanding ("MOU") with the intent to develop and implement new biosecurity capabilities in Madagascar.

Key Points: 
  • ANTANANARIVO, Madagascar and BOSTON, Sept. 25, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and the Government of the Republic of Madagascar today announced that they have entered into a Memorandum of Understanding ("MOU") with the intent to develop and implement new biosecurity capabilities in Madagascar.
  • Ginkgo's biosecurity unit, Concentric by Ginkgo, aims to support Madagascar's public health institutions with infrastructure and tools to bolster its biosecurity efforts against COVID-19 and other new or existing biological threats.
  • The partners plan to bolster biomonitoring capabilities across the African continent, to detect and respond to biological threats, following Concentric's announced partnerships with Botswana , the Democratic Republic of the Congo , and Rwanda .
  • "We look forward to our work with the Republic of Madagascar as we share a commitment to bolstering biosecurity in the country and throughout the region," said Matt McKnight, General Manager, Biosecurity at Ginkgo Bioworks.